The company continues to report consistent operating losses, including a $16.0 million net loss in 2025Q3, reflecting the intensive capital requirements of its clinical-stage research activities.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 35.5M | 18.35M | 11.18M | 4.73M | 978.42K | 1.44M |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 20.69M | 17.92M | 7.65M | 2.46M | 332.03K | 258.01K |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 17.14M | 7.72M | 3.53M | 193.58K | 646.38K | 1.18M |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | -1000K | -7.29M | 0 | 2.07M | 0 | 0 |
| Operating Income | -35.5M | -18.35M | -11.18M | -4.73M | -978.42K | -1.44M |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | -64.13% | -136.39% | -383.43% | 32.12% | - |
| EBITDA | -35.5M | -18.35M | -11.16M | -2.66M | -1.17M | -1.94M |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | -161.49% | -64.5% | -319.64% | -128.08% | 39.92% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 2.07M | 0 | 0 |
| EBIT | -35.5M | -18.35M | -11.16M | -2.66M | -1.17M | -1.94M |
| Net Interest Income | 230.63K | -141.26K | -213.13K | -584.82K | -1.1M | -690.85K |
| Interest Income | 51.58K | 0 | 104.41K | 10.72K | -575.45K | -575.45K |
| Interest Expense | -179.05K | 141.26K | 317.54K | 595.54K | 526.83K | 115.41K |
| Other Income/Expense | -1.43M | -7.02M | 25.39K | -584.82K | -713.97K | -613.88K |
| Pretax Income | -36.93M | -25.37M | -11.16M | -5.31M | -1.69M | -2.06M |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -36.93M | -25.37M | -11.16M | -5.31M | -1.69M | -2.06M |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | -155.31% | -127.39% | -109.9% | -214.04% | 17.66% | - |
| Net Income (Continuing) | -36.93M | -25.37M | -11.16M | -5.31M | -1.69M | -2.06M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 101.84K | 104.86K | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.25 | -1.96 | -1.16 | -1.06 | -0.21 | -0.26 |
| EPS Growth % | -48.65% | -68.97% | -9.43% | -404.76% | 19.23% | - |
| EPS (Basic) | - | -1.96 | -1.16 | -1.53 | -0.88 | -0.26 |
| Diluted Shares Outstanding | 29.54M | 17.28M | 9.62M | 5.03M | 8.05M | 8.05M |
| Basic Shares Outstanding | 29.54M | 17.28M | 9.62M | 3.48M | 1.93M | 8.05M |
| Dividend Payout Ratio | - | - | - | - | - | - |
Clinical-stage liquidity shortfall
As reported in financial statements, Medicus Pharma's operating expenses have trended upward, with R&D costs peaking at $10.4 million in 2025Q3, reflecting the intensive capital requirements of clinical-stage biotechnology development as the company attempts to advance its SkinJect platform through critical regulatory and trial milestones.
The company's cost structure is dominated by non-discretionary R&D spending, which exhibits significant volatility tied to the timing of clinical trial phases. Investors should monitor whether the recent stabilization in SG&A expenses indicates a disciplined approach to overhead or merely a temporary pause in administrative expansion.
Based on the provided income statement data, Medicus Pharma continues to report consistent operating losses, with the 2025Q3 period showing a net loss of $16.0 million, underscoring the lack of operational scale as the firm remains entirely dependent on external financing to sustain its ongoing research activities.
The absence of revenue generation means that every dollar of R&D and SG&A expenditure directly expands the operating deficit. This lack of operating leverage suggests that the company's financial viability is currently decoupled from operational efficiency and remains tethered to the binary success of its clinical pipeline.
According to historical quarterly filings, the company's net losses have been accompanied by periodic stock-based compensation, such as the $117.4K recorded in 2025Q2, which may further dilute existing shareholders while the firm struggles to achieve a path toward positive net income or sustainable cash flow generation.
The reliance on equity-linked compensation in a pre-revenue environment warrants caution, as it suggests management is utilizing non-cash incentives to preserve limited liquidity. Analysts should evaluate whether these compensation levels align with the achievement of tangible clinical milestones or if they represent an additional burden on equity holders.
With a debt-to-equity ratio exceeding 100% and a cash balance of only $8.7 million, the company faces significant liquidity risks, as evidenced by the rapid depletion of capital observed in the most recent quarterly reports which show substantial net losses across all tracked periods.
Short-term observers may argue that the company's high leverage indicates a lack of access to non-dilutive capital markets, potentially forcing a distressed equity raise. The current financial trajectory suggests that the company may be approaching a critical inflection point where its ability to fund future trials becomes severely compromised.
Quick answers to the most common questions about buying MDCX stock.
For fiscal year 2025, Medicus Pharma Ltd. Common Stock (MDCX) reported total revenue of $0.0M.
Medicus Pharma Ltd. Common Stock (MDCX) reported a net loss of $25.4M for the fiscal year ending 2025.